This bill prohibits health insurance carriers from denying coverage for nonopioid pain medications in favor of opioids or requiring patients to try opioids first. It requires insurers to treat FDA-approved nonopioid drugs equally to opioids in formularies, meaning coverage restrictions, prior authorization, and cost-sharing tiers must be no more restrictive for nonopioid drugs. The law applies to state health benefit plans, school employee health programs, and Medicaid for acute pain treatment. It takes effect January 1, 2026, directly affecting insurers and patients covered by these plans.
This bill would require New Jersey Medicaid to cover ovulation-enhancing drugs and related medical services without restrictions for beneficiaries experiencing infertility. It directly affects low-income New Jersey residents enrolled in Medicaid who seek infertility treatment. The key provision amends Medicaid law to explicitly include these services as a standard benefit, removing prior authorization requirements. This change would expand current coverage to ensure these treatments are accessible as routine care for eligible individuals.
This bill authorizes certified medication aides to administer medications to residents in New Jersey nursing homes, expanding their current scope of practice. It directly affects nursing homes struggling with staffing shortages and certified medication aides who would now be permitted to perform this role in nursing home settings (currently allowed in 38 states and other care facilities like assisted living residences). The key mechanism is amending existing law to explicitly include nursing homes under the certification framework for medication aides, addressing legislative findings that staffing challenges are severe in nursing homes post-pandemic. This change aims to alleviate staffing pressures by allowing medication aides to support resident care needs within existing certification standards.
This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.
This New Jersey bill creates a new crime called fertility fraud, which specifically targets licensed health care practitioners who knowingly use a patient's reproductive material without their written consent. Under the law, a practitioner commits this offense if they use their own sperm or eggs or the material of another person to cause a pregnancy without the patient's informed agreement. If convicted of this third-degree crime, the individual faces up to five years in prison, a fine of $15,000, and the mandatory permanent revocation of their medical license. Additionally, the legislation extends the statute of limitations for prosecuting this specific offense to 20 years from the date of the treatment or 10 years from when the victim discovers the fraud, whichever is later.
This bill requires state agencies to assess substance and alcohol use disorder treatment providers for conflicts of interest before approving state funding, licensure, or certification. Providers must submit detailed financial information, board member details, and lists of stakeholders with financial ties. If a conflict is identified that could affect care quality, the provider has 90 days to resolve it or risk losing funding/approval. After resolution, providers must undergo two additional conflict assessments within the next year. The law applies to all licensed or certifying state entities and defines conflicts as situations where outside financial interests might influence treatment decisions.
This bill prohibits the $0.50 surcharge on rideshare trips that are designated for paratransit service, which includes transportation for people with disabilities and Medicaid non-emergency medical transport. It directly affects users of apps like Uber and Lyft who rely on these services for accessibility needs, ensuring they are not charged the extra fee required for regular prearranged rides. The legislation also clarifies that transportation network companies are not personally liable for these specific paratransit trips. By amending existing state laws, the bill removes the financial barrier for eligible riders while maintaining the surcharge for standard rides.
This bill (A 976) creates a temporary license for nonresident military spouses who move to New Jersey due to a military spouse’s assignment. It allows these spouses to practice certain licensed professions (like nursing or social work) without full New Jersey licensure, provided they hold a current license in another state with equivalent requirements and meet other criteria like recent experience and a clean disciplinary record. Most temporary licenses are valid for one year (extendable once), but licenses for six specific professions (including nursing and social work) are valid for two years. The bill directly affects military spouses relocating with active-duty service members, enabling them to work in their licensed professions while adjusting to their new home state.
Bill A 2733 requires emergency departments in New Jersey general hospitals to provide parents or guardians of children experiencing mental health crises with contact information for nearby county-based care management organizations (CMOs). These CMOs are defined as nonprofit groups offering in-person support for youth with complex needs and their families. The bill mandates that hospitals share this specific information during emergency visits, directly affecting parents/guardians, emergency departments, and CMOs. It takes effect 90 days after enactment.
This bill regulates pharmacy benefits managers (PBMs) and insurance carriers to increase transparency and fairness in prescription drug coverage. It requires carriers and PBMs to establish pharmacy and therapeutics committees with strict conflict-of-interest rules, prohibits commission-based PBM compensation (mandating flat fees instead), and mandates detailed reporting of PBM fees for insurance filings. The law directly affects insurers, PBMs, and pharmacies by changing how drug formularies (approved drug lists) are managed and how PBM costs are calculated and disclosed. Key provisions include banning preferential formulary placement for higher-cost drugs over lower-cost generics/biosimilars and requiring actuarial documentation for PBM compensation. The bill aims to reduce patient cost-sharing and ensure PBM compensation aligns with administrative costs.
